Artificial Differences in Clostridium difficile Infection Rates Associated with Disparity in Testing


In 2015, Clostridium difficile testing rates among 30 US community, multispecialty, and cancer hospitals were 14.0, 16.3, and 33.9/1,000 patient-days, respectively. Pooled hospital onset rates were 0.56, 0.84, and 1.57/1,000 patient-days, respectively. Higher testing rates may artificially inflate reported rates of C. difficile infection. C. difficile surveillance should consider testing frequency.

Persons testing positive for Clostridium difficile by molecular methods might not always have C. difficile disease. Up to 10% of hospitalized patients carry toxigenic C. difficile; carriage rates of 35%–50% have been described in certain high-risk settings (1–4). In contrast, the risk for C. difficile infection (CDI) among hospitalized patients is 1%–2% (5).

Nucleic acid amplification testing (NAAT) has revolutionized diagnostic microbiology. Rapid, highly sensitive results can be returned to clinicians within hours, helping them make timely management decisions. The exquisite sensitivity of the test, however, has created an unexpected problem for C. difficile diagnosis: the test cannot distinguish patients with active disease from those who are asymptomatic carriers. Several clinical studies have shown that persons who test positive by NAAT without concomitant detection of toxin on conventional assays have milder disease than toxin-positive persons (6–8). The conclusion from these studies is straightforward: NAATs are highly sensitive but have an unacceptably low positive predictive value. Unnecessary clinical testing will generate many false cases; several downstream sequelae are potentially detrimental for patients and add to superfluous healthcare-associated costs.

The Study

We hypothesized that, in the era of NAAT-based testing for CDI, unevenness in testing rates introduces variability in measurement of CDI among different healthcare settings. We designed our survey to capture information about hospital characteristics and various aspects of C. difficile testing from a convenience sample of 38 medical centers, including 17 members of the Comprehensive Cancer Center Infection Control Network, 13 community hospitals, and 9 university-affiliated multispecialty centers. The survey Hospital, Willimantic, Connecticut, USA (A. Moyer, D. Mitchell); Mid State Medical Center, Meriden, Connecticut, USA (A. Moyer, D. Mitchell); Hospital of Central Connecticut, New Britain, Connecticut, USA (A. Moyer, D. Mitchell); MD Anderson Cancer Center, Houston, Texas, USA (S. Cantu); Dana Farber Cancer Institute, Boston, Massachusetts, USA (C. Hsieh); Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA (N. Warren); Moffitt Cancer Center, Tampa, Florida, USA (S. Martin); University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA (J. Willson); James Cancer Center, Columbus, Ohio, USA (J. Dickman); Seattle Cancer Care Alliance, Seattle, Washington, USA (J. Knight); University of California San Diego Hospital, San Diego, California, USA (K. Delahanty); City of Hope, Duarte, California, USA (A. Flood); Roswell Park, Buffalo, New York, USA (J. Harrington)

DOI: https://doi.org/10.3201/eid2403.170961
Artificial Differences in C. difficile Rates

Table. Hospital characteristics of study centers and methods used for the diagnosis of Clostridium difficile infection, 2015*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Community hospital, n = 11</th>
<th>Large multispecialty academic center, n = 9</th>
<th>Tertiary-care cancer center, n = 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average no. beds (range)</td>
<td>294 (156–472)</td>
<td>869 (563–1,525)</td>
<td>221 (20–660)</td>
</tr>
<tr>
<td>No. annual admissions (range)</td>
<td>12,297 (2,897–22,000)</td>
<td>38,711 (14,589–86,658)</td>
<td>9308 (459–28,400)</td>
</tr>
<tr>
<td>No. annual patient-days (range)</td>
<td>56,322 (12,249–88,241)</td>
<td>241,034 (155,140–469,664)</td>
<td>66,263 (5,832–202,483)</td>
</tr>
<tr>
<td>Average length of stay, d</td>
<td>4.76</td>
<td>7.2</td>
<td>7.95</td>
</tr>
<tr>
<td>Transplantation, no.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematopoietic stem cell</td>
<td>0</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>Solid organ</td>
<td>0</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Diagnostic test, no.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAAT, 1-step</td>
<td>7</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>NAAT, 2-step</td>
<td>2</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>No. rejections of formed fecal samples</td>
<td>10</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>Pooled HO-CDI rate/1,000 patient-days</td>
<td>0.56</td>
<td>0.87</td>
<td>1.57</td>
</tr>
</tbody>
</table>

*HO-CDI, hospital-onset C. difficile infection; NAAT, nucleic acid amplification testing.

consisted of 13 questions for the year 2015: total number of beds, admissions, oncology beds, and transplants; C. difficile testing practices (inpatient testing volume, diagnostic method, and rejection policies); and rate of hospital-onset CDI (HO-CDI). We compared rates using ordinary 1-way analysis of variance or Kruskal–Wallis and determined the Pearson coefficient to measure the strength and direction of linear relationships between testing and C. difficile infection rates. We considered p<0.05 as significant. Each hospital provided information after responding to the Institutional Review Board and Health Insurance Portability and Accountability Act considerations at its institution.

Of the 31 (82%) hospitals responding to the survey, 30 provided complete data (Table). Overall, NAAT use was 87% (82% of community hospitals, 100% of multispecialty centers, and 80% of cancer centers). Among centers with 2-step testing, the commonly used initial test was glutamate dehydrogenase with or without toxin enzyme immunoassay, followed by NAAT for indeterminate samples. The overall fecal positivity rate among centers that used a 1-step NAAT was 16% for community hospitals, 15% for multispecialty centers, and 12% for cancer centers. Among NAAT users, the positivity rate for 1-step versus 2-step tests did not differ (13.9% vs. 14.3%, respectively). Formed fecal samples were rejected at 28 of 30 hospitals. Fifteen centers implemented a formal policy to avoid testing replicate samples; 2 rejected samples from patients receiving laxatives.

We determined the testing rate for each study hospital (Figure 1). The mean number of tests per 100 admissions for 2015 was 6.4 for community hospitals, 12.2 for multispecialty centers, and 29.1 for cancer centers (p = 0.0003). The mean number of tests per 1,000 patient-days was 14.0,
16.3, and 33.9, respectively (p = 0.0016). A separate analysis on the subset of centers using PCR-based testing yielded similar results: 6.1, 12.6, and 28.0 tests/100 admissions (p = 0.0058) and 14.1, 16.3, and 33.4 tests/1,000 patient-days, respectively (p = 0.015).

The mean rate of hospital-onset \( C. \) difficile infection for the community hospitals, multispecialty centers, and cancer centers was 0.57, 0.88, and 1.57 cases per 1,000 patient-days (p = 0.0007). The correlation between testing rates, number of hospital beds, and average length of stay (Figure 2, panels A–D) illustrated a positive linear relationship between testing rates and length of stay. HO-CDI rates were highest for cancer centers that use NAAT (Figure 2, panel E).

**Conclusions**

We demonstrated that hospitals that test for \( C. \) difficile more frequently, such as cancer hospitals, have significantly higher CDI rates. This finding has 2 logical explanations. First, patients with cancer and patients in highly specialized hospitals have higher rates of HO-CDI because of the complexity of their underlying conditions and treatment. Second, and of particular importance in the era of reported healthcare-associated infections, overtesting can overdiagnose carriers of \( C. \) difficile as \( C. \) difficile cases, when in fact these patients have nondisease conditions of lesser clinical and epidemiologic significance.

Our study findings suggest that much of the excess \( C. \) difficile diagnosis in tertiary and cancer centers might be attributable to overtesting. We base our conclusion on the significant association found between testing rates and level of specialized care, particularly among cancer centers, as well as a positive correlation between testing and rates of HO-CDI. Among cancer centers, the likely explanation for excessive testing despite good diagnostic stewardship is the higher prevalence of diarrhea caused by effects of chemotherapy, newer immunotherapeutic modalities, and transplant-related gastrointestinal complications.

During the early 2000s, a hypervirulent NAP1 (North American pulsed-field gel electrophoresis type 1)
C. difficile strain emerged in North America and Europe (9,10). With the premise that early and reliable detection of CDI will enhance control, the first Food and Drug Administration–approved NAATs for C. difficile became available in 2008 (5,11). NAAT use increased sharply during 2011–2013. As of 2016, ten different molecular tests for C. difficile have been Food and Drug Administration approved. More than half of all acute care settings that report CDI rates to the National Healthcare Safety Network use NAAT-based testing (12). Reports of oversensitivity of NAAT followed the increase in use, leading to a 43%–100% increase in reported incidence rates of CDI (7,11,13).

From a reporting perspective, risk adjustments have been made during interfacility comparisons of rates of HO-CDI to account for differences in diagnostic testing methods (11). Despite the apparent association between testing rates and likelihood of false-positive results with NAATs, testing frequency for C. difficile has been overlooked as a reporting metric by the National Healthcare Safety Network.

Based on the most recent estimates from 2014, rates of HO-CDI have declined by 8% in the United States since 2011 (14). Whether some component of this is due to less testing than in previous years remains unknown. Hospitals that use NAAT that have performed better over time may have truly reduced infections or simply adjusted to the new test. Current surveillance methods do not consider the effect of testing volume on reported C. difficile rates, a common cause of artificial changes.

Our report has several limitations. First, we used a convenience sample of 30 hospitals in which cancer centers were overrepresented. Second, we did not include clinical characteristics of patients tested for C. difficile because our survey focused on comparing testing rates in several representative hospitals across the healthcare continuum.

In conclusion, CDI infection surveillance programs must recognize that testing methods and testing frequency need to be considered independently when comparing infection rates. In addition, frequency of diarrhea in hospitalized patients is an important determinant that might vary by patient–case mix and affect testing and rates of HO-CDI. Testing frequency is not only important for local quality improvement but also should be made an essential component of C. difficile reporting to standardize disease measurement, monitor effectiveness of prevention strategies, and establish meaningful trends.

About the Author
Dr. Kamboj is an infectious disease physician and director of the Infection Control Program at Memorial Sloan Kettering Cancer Center in New York. Her research interests include clinical and molecular epidemiology of C. difficile infection among transplant and oncology patients.

References

Address for correspondence: Mini Kamboj, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA; email: kambojm@mskcc.org